Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model

Overview

Journal Cancer Med

Specialty Oncology

Date 2024 Dec 18

PMID 39692281

Authors

Maria Colomba Comes

Annarita Fanizzi

Samantha Bove

Luca Boldrini

Agnese Latorre

Deniz Can Guven

Serena Iacovelli

Tiziana Talienti

Alessandro Rizzo

Francesco Alfredo Zito

Raffaella Massafra

Affiliations

Soon will be listed here.

Abstract

Background: Morphological and vascular characteristics of breast cancer can change during neoadjuvant chemotherapy (NAC). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-acquired pre- and mid-treatment quantitatively capture information about tumor heterogeneity as potential earlier indicators of pathological complete response (pCR) to NAC in breast cancer.

Aims: This study aimed to develop an ensemble deep learning-based model, exploiting a Vision Transformer (ViT) architecture, which merges features automatically extracted from five segmented slices of both pre- and mid-treatment exams containing the maximum tumor area, to predict and monitor pCR to NAC.

Materials And Methods: Imaging data analyzed in this study referred to a cohort of 86 breast cancer patients, randomly split into training and test sets at a ratio of 8:2, who underwent NAC and for which information regarding the pCR status was available (37.2% of patients achieved pCR). We further validated our model using a subset of 20 patients selected from the publicly available I-SPY2 trial dataset (independent test).

Results: The performances of the proposed model were assessed using standard evaluation metrics, and promising results were achieved: area under the curve (AUC) value of 91.4%, accuracy value of 82.4%, a specificity value of 80.0%, a sensitivity value of 85.7%, precision value of 75.0%, F-score value of 80.0%, and G-mean value of 82.8%. The results obtained from the independent test show an AUC of 81.3%, an accuracy of 80.0%, a specificity value of 76.9%, a sensitivity of 85.0%, a precision of 66.7%, an F-score of 75.0%, and a G-mean of 81.2%.

Discussion: As far as we know, our research is the first proposal using ViTs on DCE-MRI exams to monitor pCR over time during NAC.

Conclusion: Finally, the changes in DCE-MRI at pre- and mid-treatment could affect the accuracy of pCR prediction to NAC.

References

Gentile D, Sagona A, De Carlo C, Fernandes B, Barbieri E, Di Maria Grimaldi S . Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients. Breast. 2023; 69:323-329. PMC: 10070173. DOI: 10.1016/j.breast.2023.03.016. View

Fan M, Chen H, You C, Liu L, Gu Y, Peng W . Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Mol Biosci. 2021; 8:622219. PMC: 8044916. DOI: 10.3389/fmolb.2021.622219. View

Wei D, Weinstein S, Hsieh M, Pantalone L, Kontos D . Three-Dimensional Whole Breast Segmentation in Sagittal and Axial Breast MRI With Dense Depth Field Modeling and Localized Self-Adaptation for Chest-Wall Line Detection. IEEE Trans Biomed Eng. 2018; 66(6):1567-1579. PMC: 6684022. DOI: 10.1109/TBME.2018.2875955. View

Tinterri C, Fernandes B, Zambelli A, Sagona A, Barbieri E, Di Maria Grimaldi S . The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy. Cancers (Basel). 2024; 16(2). PMC: 10814808. DOI: 10.3390/cancers16020376. View

Barron A, Hoskin T, Day C, Hwang E, Kuerer H, Boughey J . Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surg. 2018; 153(12):1120-1126. PMC: 6583006. DOI: 10.1001/jamasurg.2018.2696. View

Li Y, Fan Y, Xu D, Li Y, Zhong Z, Pan H . Deep learning radiomic analysis of DCE-MRI combined with clinical characteristics predicts pathological complete response to neoadjuvant chemotherapy in breast cancer. Front Oncol. 2023; 12:1041142. PMC: 9850142. DOI: 10.3389/fonc.2022.1041142. View

Cattell R, Chen S, Huang C . Robustness of radiomic features in magnetic resonance imaging: review and a phantom study. Vis Comput Ind Biomed Art. 2020; 2(1):19. PMC: 7099536. DOI: 10.1186/s42492-019-0025-6. View

Mann R, Kuhl C, Kinkel K, Boetes C . Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008; 18(7):1307-18. PMC: 2441490. DOI: 10.1007/s00330-008-0863-7. View

Eun N, Kang D, Son E, Park J, Youk J, Kim J . Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology. 2019; 294(1):31-41. DOI: 10.1148/radiol.2019182718. View

10.

Tong T, Li D, Gu J, Chen G, Bai G, Yang X . Dual-Input Transformer: An End-to-End Model for Preoperative Assessment of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Ultrasonography. IEEE J Biomed Health Inform. 2022; 27(1):251-262. DOI: 10.1109/JBHI.2022.3216031. View

11.

Tasoulis M, Lee H, Yang W, Pope R, Krishnamurthy S, Kim S . Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. JAMA Surg. 2020; 155(12):e204103. PMC: 7542519. DOI: 10.1001/jamasurg.2020.4103. View

12.

Massafra R, Comes M, Bove S, Didonna V, Gatta G, Giotta F . Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy. J Pers Med. 2022; 12(6). PMC: 9225219. DOI: 10.3390/jpm12060953. View

13.

Eun N, Son E, Gweon H, Kim J, Youk J . Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients. Eur Radiol. 2019; 30(3):1460-1469. DOI: 10.1007/s00330-019-06539-4. View

14.

Comes M, La Forgia D, Didonna V, Fanizzi A, Giotta F, Latorre A . Early Prediction of Breast Cancer Recurrence for Patients Treated with Neoadjuvant Chemotherapy: A Transfer Learning Approach on DCE-MRIs. Cancers (Basel). 2021; 13(10). PMC: 8151784. DOI: 10.3390/cancers13102298. View

15.

Gentile D, Martorana F, Karakatsanis A, Caruso F, Caruso M, Castiglione G . Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: A retrospective study. Eur J Surg Oncol. 2024; 50(12):108732. DOI: 10.1016/j.ejso.2024.108732. View

16.

La Forgia D, Vestito A, Lasciarrea M, Comes M, Diotaiuti S, Giotta F . Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI. J Pers Med. 2021; 11(4). PMC: 8065517. DOI: 10.3390/jpm11040256. View

17.

Lin T, Goyal P, Girshick R, He K, Dollar P . Focal Loss for Dense Object Detection. IEEE Trans Pattern Anal Mach Intell. 2018; 42(2):318-327. DOI: 10.1109/TPAMI.2018.2858826. View

18.

Comes M, Fanizzi A, Bove S, Didonna V, Diotaiuti S, La Forgia D . Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs. Sci Rep. 2021; 11(1):14123. PMC: 8266861. DOI: 10.1038/s41598-021-93592-z. View

19.

Mann R, Cho N, Moy L . Breast MRI: State of the Art. Radiology. 2019; 292(3):520-536. DOI: 10.1148/radiol.2019182947. View

20.

Jahani N, Cohen E, Hsieh M, Weinstein S, Pantalone L, Hylton N . Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration. Sci Rep. 2019; 9(1):12114. PMC: 6702160. DOI: 10.1038/s41598-019-48465-x. View